Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.36 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | CHAT | P28329 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567985 | 0.98 | TSHR (0.44) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| SCHEMBL29566694 | 0.98 | TSHR (0.44) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| SCHEMBL15525175 | 0.95 | MYC (0.42) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| SCHEMBL6914928 | 0.95 | MYC (0.42) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| SCHEMBL6915014 | 0.95 | MYC (0.42) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| SCHEMBL6913794 | 0.95 | MYC (0.42) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| SCHEMBL6916728 | 0.95 | MYC (0.42) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| Hydrochloric Acid SCHEMBL11754062 | 0.95 | MYC (0.42) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| SCHEMBL6917455 | 0.95 | MYC (0.42) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| SCHEMBL6913540 | 0.95 | MYC (0.42) | MYCTSHRSMN1; SMN2TTRFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394995-B2 | Process for preparation of carbonyl compound and pro-oxidant for preparation of carbonyl compound | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2013-03-12 | — | — | US | disclosed |
| EP-2085373-B1 | METHOD FOR PRODUCING CARBONYL COMPOUND AN PRO-OXIDANT USED FOR PRODUCTION OF CARBONYL COMPOUND | UNIV NAGOYA NAT UNIV CORP (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20100041917-A1 | PROCESS FOR PREPARATION OF CARBONYL COMPOUND AND PRO-OXIDANT FOR PREPARATION OF CARBONYL COMPOUND | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2085373-A1 | METHOD FOR PRODUCING CARBONYL COMPOUND AN PRO-OXIDANT USED FOR PRODUCTION OF CARBONYL COMPOUND | National University Corporation Nagoya University (JP) | 2009-08-05 | — | — | EP | disclosed |
| EP-1201238-A1 | SULFONAMIDE DERIVATIVES AND REMEDIES FOR ALLODYNIA | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041917-A1 | PROCESS FOR PREPARATION OF CARBONYL COMPOUND AND PRO-OXIDANT FOR PREPARATION OF CARBONYL COMPOUND | CBR1, CBR3, NOX4 | MYC 484/4885TSHR 3093/4885SMN1; SMN2 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.